AbCellera, Gilead collaborate for new multi-year, multi-target antibody discovery
Expanded collaboration includes an eight-target discovery partnership leveraging AbCellera’s entire technology stack
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
Gilead Sciences
Gilead, Novo Nordisk expand NASH clinical collaboration
Triple combination regimen to be investigated in new Phase 2b study in NASH patients with cirrhosis
Gilead, Merck sign pact to develop, commercialise long-acting HIV treatment combinations
Collaboration to focus on oral and injectable formulations of Lenacapavir and Islatravir
Healthcare industry records 103 deals worth $55.3 billion in December 2020
One big-ticket deal contributes 70.5 per cent of the total deal value in December 2020
Gilead, Galapagos amend commercialisation and development pact for Jyseleca (filgotinib)
Under the new arrangement, Galapagos will assume sole responsibility in Europe for filgotinib in RA, Gilead to receive royalties…
Gilead Sciences to acquire MYR GmbH
Gilead to acquire Hepcludex, a first-in-class entry inhibitor, for treatment of chronic hepatitis delta virus (HDV), after closing…
Gilead Sciences, AIDS Society of India survey highlights disruption in HIV care during COVID-19
Main reasons for disruption in India include travel constraints, fear of getting COVID-19
Trodelvy from Immunomedics extends survival in breast cancer patients
The FDA granted the drug accelerated approval for its use in metastatic triple-negative breast cancer (mTNBC) patients who had…
Saptagir Labs signs manufacturing deal with Jubilant Generics for remdesivir
The drug will be produced at its sterile drug product manufacturing plant in Hyderabad which is WHO GMP certified
Gilead may soon buy Immunomedics in deal over $20 billion
The deal, which will expand Gilead’s oncology portfolio, might get announced tomorrow if not sooner, inform reports